Get the Stockscreener App
1,148.18
2.89%
-33.69
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,148.18, with a volume of 656.32K.
It is down -2.89% in the last 24 hours and up +1.30% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,181.87
Open:
$1166.01
24h Volume:
656.32K
Relative Volume:
0.21
Market Cap:
$1.02T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
41.33
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
-7.11%
1M Performance:
+1.30%
6M Performance:
+6.94%
1Y Performance:
+43.59%
1-Day Range:
$1,140.74
$1,166.01
1-Week Range:
$1,140.74
$1,241.89
52-Week Range:
$623.78
$1,249.45
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,147.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.66 | 620.51B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
244.05 | 438.16B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
121.01 | 306.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.79 | 292.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Zimmer Biomet, 20 Indiana Companies On Time’s Best Companies List - InkFreeNews.com
Bernstein raises Eli Lilly stock price target on beat potential - Investing.com
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? - AOL.com
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? - The Motley Fool
Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum - ChartMill
Bernstein Adjusts Price Target on Eli Lilly and Co. to $1,385 From $1,300, Maintains Outperform Rating - marketscreener.com
Why Are Eli Lilly (NYSE:LLY) Medicines Shaping Healthcare Trends? - Kalkine Media
Peptron chief Choi buys shares, signals confidence in Lilly tie-up and techCHOSUNBIZ - Chosunbiz
7th Circuit restores breach-of-contract case against Eli Lilly - Indianapolis Business Journal
7th Circ. Revives Teva Suit Over Eli Lilly Generic Drug Block - Law360
US appeals court revives Teva lawsuit over Lilly osteoporosis drug - Reuters
Teva lawsuit against Eli Lilly over Forteo revived by appeals court - Investing.com South Africa
Teva Revives Lilly Contract Suit Over Copy of Bone-Loss Drug - Bloomberg Law News
Prediction: 1 New Reason Eli Lilly Stock Could Still Be Headed Higher - 24/7 Wall St.
LLY Maintained by Guggenheim -- Price Target Lowered to $1273 - GuruFocus
Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades - Benzinga
Guggenheim raises Eli Lilly stock price target on tirzepatide strength - Investing.com
Eli Lilly stock holds steady as obesity and diabetes drugs reshape its long term growth story - ad-hoc-news.de
Guggenheim Adjusts PT on Eli Lilly and Co. to $1,273 From $1,235, Maintains Buy Rating - marketscreener.com
Novo reports growth in prescription numbers and maintains its lead over Eli Lilly - medwatch.com
Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors - Yahoo Finance
Lobbying Update: $80,000 of ELI LILLY AND COMPANY lobbying was just disclosed - Quiver Quantitative
GLP-1 Maker Lilly Funded Clinical Trials at Chinese Military Site - Small Wars Journal
Tampa General Hospital sues major pharmaceutical company over drug pricing - Tampa Bay Times
Historic Indianapolis Home Built for an Early Eli Lilly Exec Lists for $8M - Mansion Global
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY) - The Globe and Mail
Should You Buy Eli Lilly Stock? Here's My Honest Take. - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
Is Eli Lilly and Co (LLY) a Bargain After 2.3% Drop? GF Value Sa - GuruFocus
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Eli Lilly (LLY) Wins Canada Backing For Ebglyss As Oncology Progress Builds - simplywall.st
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands - Investorideas.com
Lilly stock holds steady as diabetes and obesity portfolio scales up in global demand - ad-hoc-news.de
Eli Lilly stock reflects strong pharma growth and pipeline momentum - ad-hoc-news.de
The Oral GLP-1 Tracker: Lilly’s Foundayo launch remains ‘muted’ - Fierce Pharma
Peptron says Lilly research remains on track as Mounjaro remarks send shares to lower limit - koreabiomed.com
LLY Stock Could Break Above $1,240 as Eli Lilly’s Obesity Drug Growth Drives Record Rally - FXLeaders
Eli Lilly Rides Surging GLP-1 Demand Amid 11% U.S. Adoption - NAI500
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Hovers Near $1,200 as Focus Stays on $50 Obesity Drug Access - TechStock²
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma - 24/7 Wall St.
/C O R R E C T I O N -- Eli Lilly and Company/ - Lilly Investor Relations
Ebglyss Receives Positive Reimbursement Recommendation from Cana - GuruFocus
Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company - Encyclopedia Britannica
Tampa General sues Eli Lilly for allegedly pulling 340B discounts - Healthcare Finance News
Truist Financial Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,370 - Moomoo
Eli Lilly's Ebglyss Gains Momentum After Positive Reimbursement Recommendation - GuruFocus
Lilly was already pharma's biggest company. Now it's doing deals to match - Endpoints News
Eli Lilly to Present Key Alzheimer's Research at AAIC 2026 - GuruFocus
Eli Lilly (LLY) to Showcase Research at 2026 Alzheimer's Conference - GuruFocus
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):